Product logins

Find logins to all Clarivate products below.


注目すべき重要なトレンド

2025年以降の医薬品開発および患者さんの健康アウトカムを方向付けるトレンド。​

ニーマンピック病C型(NPC)に対して米国で初めての医薬品が承認されるなど、2024年は規制環境が「初めて」に溢れた年でした。脂肪肝により肝臓の瘢痕化を生じている患者にとって初めての治療選択肢が米国市場に参入しました。初めての腫瘍浸潤リンパ球(TIL)を使用したがん治療薬が、同分野での30年以上にわたる研究の末、規制当局からの承認を受領しました。

これらのトレンドは、業界の継続的な技術革新と、高いアンメットニーズが存在する患者集団の治療ギャップを埋めようとする当局の積極的な取り組みを示すものです。

詳細はこちら

Key trends

Drug combinations: your questions answered Drug combinations: your questions answered
Blog November 19, 2024
Drug combinations: your questions answered

Developing drug combinations is a complex process with challenges and opportunities that can significantly impact patient outcomes. Diseases such as cancer often involve multiple molecular pathways, so single drugs may…

These seven ADC makers are developing therapies that show promise for hard-to-treat cancers These seven ADC makers are developing therapies that show promise for hard-to-treat cancers
Blog June 17, 2024
These seven ADC makers are developing therapies that show promise for hard-to-treat cancers

It has been a long, slow road to the recent frenzy in antibody drug conjugate (ADC) activity. After the first publication of an experimental ADC design 60 years ago, it…

What a string of semaglutide biosimilars could mean for Mainland China What a string of semaglutide biosimilars could mean for Mainland China
Blog May 14, 2024
What a string of semaglutide biosimilars could mean for Mainland China

The Mainland China market for GLP-1 drugs to treat obesity and diabetes is valued at approximately $1.7 billion.

Real world data reveal how diseases manifest in diverse populations Real world data reveal how diseases manifest in diverse populations
Blog April 4, 2024
Real world data reveal how diseases manifest in diverse populations

The prevalence and co-occurrence of immune-mediated inflammatory diseases (IMIDs) like inflammatory bowel disease and rheumatoid arthritis varies by race and ethnicity among U.S. adults. That’s the upshot of a retrospective…

chevron_left
chevron_right